These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22984648)

  • 21. Prolactin Levels After Switching to Paliperidone Palmitate in Patients with Schizophrenia.
    Nakamura M; Nagamine T; Sato G; Besho K
    Innov Clin Neurosci; 2016; 13(5-6):28-30. PubMed ID: 27800283
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
    Remmerie B; De Meulder M; Ariyawansa J; Savitz A
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):538-547. PubMed ID: 27363344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly.
    Geerts H; Spiros A; Roberts P; Alphs L
    Schizophr Res; 2018 Jul; 197():261-268. PubMed ID: 29395607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics.
    de Leon J
    Neuropharmacology; 2020 May; 168():107656. PubMed ID: 31150659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Owen RT
    Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.
    Marchese G; Pittau B; Casu G; Peddio G; Spada GP; Pira M; Deriu A; Portesani F; Pisu C; Lazzari P; Pani L
    Eur Psychiatry; 2010 Mar; 25(2):92-100. PubMed ID: 19640686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
    Brittain ST; Wheless JW
    Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
    Ereshefsky L; Mascarenas CA
    J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder.
    Chou YH; Chu PC; Wu SW; Lee JC; Lee YH; Sun IW; Chang CL; Huang CL; Liu IC; Tsai CF; Yen YC
    Clin Psychopharmacol Neurosci; 2015 Aug; 13(2):121-8. PubMed ID: 26243837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.
    Samtani MN; Sheehan JJ; Fu DJ; Remmerie B; Sliwa JK; Alphs L
    Clin Pharmacol; 2012; 4():25-40. PubMed ID: 22888277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.
    Mannaert E; Vermeulen A; Remmerie B; Bouhours P; Levron JC
    Encephale; 2005; 31(5 Pt 1):609-15. PubMed ID: 16598965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
    Ostuzzi G; Bertolini F; Del Giovane C; Tedeschi F; Bovo C; Gastaldon C; Nosé M; Ogheri F; Papola D; Purgato M; Turrini G; Correll CU; Barbui C
    Am J Psychiatry; 2021 May; 178(5):424-436. PubMed ID: 33596679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.
    Gharabawi GM; Gearhart NC; Lasser RA; Mahmoud RA; Zhu Y; Mannaert E; Naessens I; Bossie CA; Kujawa M; Simpson GM
    Ann Gen Psychiatry; 2007 Jan; 6():3. PubMed ID: 17261186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.
    Emsley R; Kilian S
    Neuropsychiatr Dis Treat; 2018; 14():205-223. PubMed ID: 29379293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.